BACKGROUND: Androgen deprivation therapy (ADT) might increase the risk of acute kidney injury (AKI) in patients with prostate cancer (PCa).
OBJECTIVE: To examine the impact of ADT on AKI in a large contemporary cohort of patients with nonmetastatic PCa representing the US population.
DESIGN, SETTING, AND PARTICIPANTS: Overall, 69 292 patients diagnosed with nonmetastatic PCa between 1995 and 2009 were abstracted from the Surveillance Epidemiology and End Results-Medicare database.
OUTCOMES MEASUREMENTS AND STATISTICAL ANALYSES: Patient in both treatment arms (ADT vs no ADT) were matched using propensity-score methodology. Ten-year AKI rates were estimated. Competing-risks regression analyses tested the association between ADT and AKI, after adjusting for the risk of death during follow-up.
RESULTS AND LIMITATIONS: Overall, the 10-yr AKI rates were 24.9% versus 30.7% for ADT-naive patients versus those treated with ADT, respectively (p< 0.001). When patients were stratified according to the type of ADT, the 10-yr AKI rates were 31.1% versus 26.0% for men treated with gonadotropin-releasing hormone (GnRH) agonists and bilateral orchiectomy, respectively (p< 0.001). In multivariable analyses, the administration of GnRH agonists (hazard ratio [HR]: 1.24; 95% confidence interval [CI], 1.18-1.31; p< 0.001), but not bilateral orchiectomy (HR: 1.11; 95% CI, 0.96-1.29; p=0.1), was associated with the risk of experiencing AKI. Our study is limited by its retrospective design.
CONCLUSIONS: ADT is associated with an increased risk of AKI in patients with nonmetastatic PCa. In particular, the administration of GnRH agonists, but not surgical castration, may substantially increase the risk of experiencing AKI. These observations should help provide physicians with better patient selection to reduce the risk of AKI.
PATIENT SUMMARY: The administration of gonadotropin-releasing hormone agonists, but not bilateral orchiectomy, increases the risk of acute kidney injury (AKI) in patients with prostate cancer (PCa). These observations should help provide physicians with better patient selection to reduce the risk of AKI in PCa patients.
Written by:
Gandaglia G, Sun M, Hu JC, Novara G, Choueiri TK, Nguyen PL, Schiffmann J, Graefen M, Shariat SF, Abdollah F, Briganti A, Montorsi F, Trinh QD, Karakiewicz P. Are you the author?
Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada; Urological Research Institute, Vita-Salute San Raffaele University, Milan, Italy; Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Department of Surgery, Oncology, and Gastroenterology-Urology Clinic, University of Padua, Padua, Italy; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Department of Radiation Oncology, Division of Urology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Martini-Klinik, University-Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Surgery, Division of Urology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Reference: Eur Urol. 2014 Jan 28. pii: S0302-2838(14)00095-5.
doi: 10.1016/j.eururo.2014.01.026
PubMed Abstract
PMID: 24495466
UroToday.com Prostate Cancer Section
